...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

ARTES Steps Further Into the Vaccine Business by Acquiring Anavax

| Print |
Monday, 27 September 2010 09:15 (UTC + 2)

ARTES_logo

Langenfeld, Germany, September 27, 2010 / b3c newswire / - ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases.

 

With the combination of two excellent technology platforms, ANAVAX and the Hansenula expression system, ARTES has positioned itself as a unique partner for the vaccine industry.

 

The ANAVAX VLP platform has already been applied to the development of adjuvant-free vaccines against avian and swine flu, malaria and HIV. Hansenula is the preferred technology for affordable mass vaccination and is recommended by the WHO for hepatitis B vaccination campaigns. Together, the platforms build a new approach to low-cost mass production of safe and effective vaccines. ARTES’ business plan is to enhance its position as a preferred development partner for vaccine manufacturer.

 

 

Virus-like particles: VLPs
VLPs are small packages of artificially produced viral proteins that assemble either spontaneously or are embedded in a lipid membrane during protein synthesis. As a safe and efficient technology platform, VLPs are of increasing interest for the presentation of new antigens. The structural similarity to viruses together with the complete lack of infectious material is a major advantage over conventional vaccines.

 

Anavax
The ANAVAX technology was developed by scientists at the Burnet Institute in Melbourne.
First vaccine candidates targeting different flu viruses, malaria, HIV and HCV showed positive results in preclinical studies.
The Burnet Institute and ARTES will further collaborate to develop processes for specific vaccines.


ARTES’ Hansenula platform
This yeast expression platform has been applied to the production of more immunogenic hepatitis B VLP vaccines and provides an excellent base for balanced co-expression of individual proteins. The reliability and attractiveness of the Hansenula platform has been demonstrated by a number of products already marketed worldwide and by several others in clinical trials.


About ARTES Biotechnology GmbH – www.artes-biotechnology.com
ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development in microbial expression systems. ARTES offers generation of optimized production cell lines and process development based on proprietary technologies. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850-square meter S1 facilities in Langenfeld near Duesseldorf. The company focuses on contract R&D for white and red biotechnology products and on the development of new vaccine targets.


Contact

ARTES Biotechnology GmbH
Dr. Melanie Piontek
Business Development Director
+49 (0)2173 275870
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Elisabeth-Selbert-Straße 9
40764 Langenfeld